

**Ashraf S. Ibrahim, Ph.D.** Professor of Medicine, David Geffen School of Medicine at UCLA  
Division of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center

Dr. Ibrahim is a Professor of Medicine at David Geffen School of Medicine at UCLA, and a senior researcher and Director of the Graduate Studies Program at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. He received his B.Sc. in Biochemistry-Microbiology in 1986 from Kuwait University with honors. He then attended Post graduate school at Loughborough University of Technology, UK where he obtained a Ph.D. degree in Microbial Physiology in 1991 under the mentorship of Professors R.J. Stretton and M. A. Ghannoum. Dr. Ibrahim completed his Postdoctoral training in Infectious Diseases in the laboratory of Dr. John Edwards, Jr. at Harbor-UCLA Medical Center. Dr. Ibrahim's research focuses on molecular pathogenesis, host-pathogen interactions, immunotherapies, and models of infections to advance the understanding of the pathogenic mechanisms and virulence factors of fungal and bacterial infections and translate this knowledge into novel therapeutic strategies. His research is focused on the following areas: 1) The host-pathogen interactions in mucormycosis and the development of rapid diagnostics and novel antibody-based therapy; 2) Unnatural immunity for the development of vaccine strategies that target multidrug resistant organisms including MDR *Candida* species, and Gram-negative bacteria; 3) Mechanisms of microbial sepsis for development of novel immunotherapies; and 4) Antifungal drug discovery.

Dr. Ibrahim currently holds several NIH and industry-sponsored projects and has received over \$30 M in funding for his research. He coauthored >200 peer-reviewed research papers, review articles book chapters and conference proceeding. He is an elected member of the American Academy of Microbiology and a receiver of several prestigious awards for excellence in research. For the last 15 years, Dr. Ibrahim served on numerous NIH study sections as an Ad Hoc reviewer, and just concluded his tenure (2019-2023) as a standing review member of the National Institute of Allergy and Infectious Diseases (NIAID) Drug Discovery and Molecular Pharmacology A (DMPA) and Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) study sections.